Anti-TNF drugs have been meanwhile approved for the treatment of various chronic inflammatory conditions of autoimmune origin, such as RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. This evidence concerns the gene TNF and rheumatoid arthritis.